The target audience of this program is attendees of the IDWeek 2015 Conference.
Specifically, healthcare professionals in infectious
diseases and healthcare epidemiology and prevention, including researchers, clinicians, quality and patient safety practitioners,
epidemiologists, and public health officials, including those who see HIV and pediatric patients.
Upon completion of this program, participants should be able to:
- Differentiate between the 3 available testing methods for LTBI
- Identify the clinical utility of IGRAs when testing immunocompromised patients for TB
- Determine the epidemiology and incidence of TB and CMV infections in immunocompromised patients
- Discuss new data on the role that IGRAs may play in the prediction of CMV infection
- Describe the clinical value of IGRAs on preemptive or prophylaxis strategies for CMV
- Assess one institution's guidelines for how to handle positive IGRA test results in HCW screening
- Discuss case studies demonstrating the importance of screening HCWs for LTBI
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council
for Continuing Medical Education through the joint sponsorship of CME Outfitters, LLC, and Jespersen & Associates, LLC.
CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM.
Physicians should claim only
the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses): Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 2.0 contact hours.
Commercial Support Statement
This program is supported by an educational grant from Oxford Immunotec.